Glucocorticoids for acute viral bronchiolitis in infants and young children

Area of Science:

• Pediatric Respiratory Medicine
• Clinical Pharmacology
• Evidence-Based Medicine

Background:

• Acute viral bronchiolitis is a common respiratory infection in infants and young children.
• Current treatments for bronchiolitis are largely supportive, with limited options for pharmacological intervention.
• The role of glucocorticoids in managing bronchiolitis remains controversial.

Purpose of the Study:

• To evaluate the effectiveness of glucocorticoids, alone or with bronchodilators, in treating acute viral bronchiolitis.
• To assess the impact on admission rates, length of stay, and clinical severity.
• To determine if glucocorticoid therapy increases adverse effects in pediatric patients.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials.
• Inclusion of studies involving systemic or inhaled glucocorticoids in infants and young children with acute viral bronchiolitis.
• Analysis of outcomes including hospitalization, length of stay, clinical scores, and adverse events.

Main Results:

• No consistent clinically relevant association found between single-agent glucocorticoid therapy (systemic or inhaled) and improved outcomes in outpatients or inpatients.
• Exploratory findings suggest a potential benefit of combined glucocorticoids and nebulized epinephrine in reducing outpatient hospitalization rates.
• These combined therapy findings require cautious interpretation due to limited evidence.

Conclusions:

• Single-agent glucocorticoid therapy is not consistently associated with improved clinical outcomes in acute viral bronchiolitis.
• Combined glucocorticoids and nebulized epinephrine may offer a potential benefit for reducing hospitalizations in outpatients, warranting further investigation.
• Current evidence does not support routine use of glucocorticoids for acute viral bronchiolitis outside of specific clinical trial contexts.